Drug Guidance
Complement inhibitors for treating paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome
Condition
Blood and Immune System
6 February 2026
-
Published on 06 February 2026
Last Updated on 06 February 2026
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Eculizumab 300 mg concentrate for solution for infusion as monotherapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) in adults and children.
Funding Status
Eculizumab 300 mg concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 April 2026.
Eculizumab should be used in line with the additional clinical criteria listed in the Annex.
MAF assistance does not apply to iptacopan or ravulizumab for treating PNH or aHUS.